| 发明名称 | Bladder cancer tumor marker, antibody and use thereof | ||
| 摘要 | Provided in the present invention are an aberrantly glycosylated integrin, AG-α3β1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-α3β1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer. | ||
| 申请公布号 | US9073995(B2) | 申请公布日期 | 2015.07.07 |
| 申请号 | US201113814446 | 申请日期 | 2011.08.12 |
| 申请人 | Institute of Biophysics, Chinese Academy of Sciences | 发明人 | Li Chong;Fan Zusen;Zhang Honglian;Dai Zhonghua;Tang Haidong;Chen Jun |
| 分类号 | G01N33/53;C07K16/00;C07K16/28;C07K14/705;G01N33/574;G01N33/68;C12N15/113;C12Q1/48;C12Q1/02;A61K47/48;A61K51/10;A61K45/06;A61K39/395;C07K16/30;C12N9/10 | 主分类号 | G01N33/53 |
| 代理机构 | Osha Liang LLP | 代理人 | Osha Liang LLP |
| 主权项 | 1. A binding molecule directed agains an aberrantly glycosylated integrin AG-α3β1, wherein the AG-α3β1 comprises a carbohydrate [3OSO3]Galβ1-4(Fucα1-3)[6OSO3]GlcNAc as an antigenic epitope having a structure of: wherein the binding molecule recognises or binds to the carbohydrate and is an anti-AG-α3β1 monoclonal antibody BCMab1 secreted by a hydridoma call line deposited as CGMCC No. 3845. | ||
| 地址 | Beijing CN | ||